About This Test
Prostate health index (PHI) combines three PSA forms (total PSA, free PSA, and p2PSA) into a single score. p2PSA test measures the proPSA concentration in serum. ProPSA is one of the isoform of free PSA which has been determined to be most specific to Prostate cancer. PHI demonstrates a significant improvement in clinical specificity for prostate cancer detection, relative to PSA alone in men 50 years of age or older with a PSA range of 2-10 ng/mL and with non-suspicious digital rectal exam (DRE) findings. At 95% clinical sensitivity, the clinical specificity for PHI is 18.2% as compared to 6.6% for free PSA in diagnostic grey zone. A low PHI result indicates lower risk of Prostate cancer, while an elevated PHI result may suggest that a prostate biopsy is necessary to rule out cancer.
Home Collection
✓ Available
Reports Available In
2 Days
Preparation / Prerequisite
2 mL (1 mL min.) Serum from 1 SST. Ship refrigerated or frozen. Do not draw sample within 7 days of Digital Rectal Examination (DRE) or Rectal Prostatic Ultrasonography.
Frequently Asked Questions
Outsourced test are being done from Dr. Lal Path Lab. Charges and reporting time is same as of Dr. Lal Path Labs.
Do not give sample within 7 days of Digital Rectal Examination (DRE) or Rectal Prostatic Ultrasonography.
The PHI (Prostate Health Index) test is important because it helps assess the risk of prostate cancer more accurately than total PSA alone, aiding early detection and reducing unnecessary biopsies.
TAT Policy
The Turnaround Time (TAT) depends on the following factors:
- Registration date and time
- Type of scan or test
- Scan time or sample collection time
In uncommon circumstances, TAT may be delayed due to test complexity or reasons beyond our control. You will be informed of the estimated TAT at the time of registration.
